FDA, CDRH Receive Slight Boosts From Senate In 2016 Funding Bill
This article was originally published in The Gray Sheet
Executive Summary
The Senate Appropriations Committee approved $10 million more in FDA funding and $1 million more in CDRH funding in 2016 than House Appropriators did in a July 16 markup, and $2 million for a Precision Medicine Initiative next year, falling far short of the President’s $10 million request for the initiative.
You may also be interested in...
Novartis Targets Ten Indications For Cosentyx
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Zydus Cadila Strides Ahead With NASH Filing In India
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
Interview: Double Delight For ImmuPharma's Dimitriou
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: